Edison Investment Research, a leading international investment research firm, announces the initiation of coverage of Mesoblast (MSB: ASX), an Australian-headquartered biotechnology company focused on adult stem therapies.
Mesoblast's pipeline is based on its proprietary mesenchymal precursor cell (MPC) and culture-expanded mesenchymal stem cell (MSC) technologies. Edison's report, Precursor to success, discusses Mesoblast's two technology platforms (MPCs and MSCs) that have to date generated nine clinical candidates (four in Phase III, five in Phase II). The report goes on to analyse the three strategic partnerships with Teva, JCR and Lonza, which underpin the key late-stage programmes including Revascor that could provide US$4bn potential peak sales.
Edison's healthcare team value Mesoblast at A$2.6bn (A$8.07/share) based on a risk-adjusted net present value (rNPV) analysis, which could rise to A$3.2bn (A$10.00/share) if upcoming catalysts are positive.
SOURCE Edison Investment Research
- Forums
- ASX - By Stock
- MSB
- analysts
analysts, page-34
Featured News
Add MSB (ASX) to my watchlist
|
|||||
Last
$1.10 |
Change
0.005(0.46%) |
Mkt cap ! $1.250B |
Open | High | Low | Value | Volume |
$1.09 | $1.13 | $1.08 | $3.990M | 3.621M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
39 | 40609 | $1.10 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.10 | 44181 | 18 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
47 | 69423 | 1.090 |
18 | 125928 | 1.085 |
30 | 202254 | 1.080 |
10 | 83907 | 1.075 |
26 | 604339 | 1.070 |
Price($) | Vol. | No. |
---|---|---|
1.095 | 7442 | 2 |
1.100 | 83277 | 23 |
1.105 | 80583 | 11 |
1.110 | 33775 | 14 |
1.115 | 24030 | 7 |
Last trade - 14.05pm 10/07/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, CEO
Charles Armstrong
CEO
SPONSORED BY The Market Online